Control of Oocyte Maturation

点击翻译按钮获取中文摘要

PROJECT SUMMARY (See instructions): The overall purpose of this research is to develop a gamete-based, nonhormonal female contraceptive. The most practical approach to an oocyte-specific nonhormonal contraceptive involves targeting of the phosphodiesterase (PDE)-regulated metabolism of cyclic adenosine monophosphate (cAMP) [a central controller of meiotic resumption upstream of M-phase Promoting Factor (MPF)], or direct targeting of activators or inhibitors of MPF. The principal regulator of cAMP in the follicle is PDE3. Cyclic guanosine monophosphate (cGMP) [produced in cumulus granulosa cells of the follicle, and transported to the oocyte via gap junctions] is an endogenous inhibitor of PDE3. PDE5 is the principal cGMP-degrading enzyme in follicle cells, and PDE9 is the only cGMP-degrading enzyme in the oocyte. The oocyte-specific protein kinase WEE2 is an essential regulator of MPF necessary for resumption of meiosis and for exit from metaphase II following fertilization. Our research plan is to develop and test inhibitors of these targets in nonhuman primates and to ultimately perform a contraceptive trial in macaques. The Specific Aims are: (1) To develop novel PDE and WEE2 inhibitors and determine if selected agents can disrupt timely meiotic maturation of the macaque oocyte; (2) To evaluate the pharmacoklnetics and pharmacodynamics of existing and novel PDE inhibitors and WEE2 inhibitors; and (3) To determine whether PDE and WEE2 inhibitors can function as contraceptive agents in regularly cycling macaques in group-mating situations. Experimental designs will include characterization of drug-target interactions, rational inhibitor design, high throughput screening and medicinal chemistry (Aim 1); testing of candidate agents for activity in vitro using incubation, in vitro fertilization, and intracytoplasmic sperm injection of macaque oocytes (Aim 1); Assessment of pharmacokinetic and phamacodynamic effects of candidate inhibitors in macaques in vivo with optimization of drug delivery (e.g. oral, vaginal ring, implant) systems and monitoring of non-target effects (Aim 2); and then conducting a contraceptive experiment in socially-housed female macaques (Aim 3). This approach is expected to establish the potential for PDE and WEE2 inhibitors as contraceptive agents for women.